Werewolf Therapeutics, Inc. (HOWL): Price and Financial Metrics
HOWL Price/Volume Stats
| Current price | $2.48 | 52-week high | $8.19 |
| Prev. close | $2.56 | 52-week low | $1.66 |
| Day low | $2.43 | Volume | 413,100 |
| Day high | $2.59 | Avg. volume | 363,582 |
| 50-day MA | $2.28 | Dividend yield | N/A |
| 200-day MA | $4.01 | Market Cap | 108.38M |
HOWL Stock Price Chart Interactive Chart >
Werewolf Therapeutics, Inc. (HOWL) Company Bio
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
HOWL Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...